🔥The 9th Round of Easy Loan, Earn $40 Reward is in progress❗️ ⏰ Promotion Period: January 15th - Feburary 15th, 2025 👉 Register now and check more details at gate.io/campaigns/358

Such an important topic, so common but ignored. A session at #ECTRIMS 2025 is needed

Bove: SOPRANINO study. Ocrelizumab Ocrevus was undetectable in blood of infants being nursed by mothers with MS being treated with this monoclonal antibody. Also, B cell counts in newborns were reassuringly normal (important for infant vaccines). #ECTRIMS2024

Exciting science and new treatment options for relapsing and progressive #MS. The Alfred MSNI service is proud to be one of two sites in Australia selected to run #CAR-T cell trials in MS. Thanks Associate Professor Mastura Monif for your leadership!

Congratulations Chao Zhu on presenting this important work on #PIRA in #MS. The main message is clear- #PIRA events improve in at least 33% of cases and can be modified by Highly active #DMTs. Helmut butzkueven MSBase Registry

Well done Sudarshini Ramanathan !!

Fantastic session on real world evidence - women are treated less in total and less effective ☹️Sandra Vukusic thanks for investigating in 🇫🇷 ….

Out now! New ‘Brain health: time matters’ report launched with latest advances and needs in MS, NMOSD, MOGAD. Gvts must act on policy changes needed to reduce disability and improve quality of life. Milestone report! @GavinGiovannoni Neurological Alliance Australia msbrainhealth.org

Thanks to everybody who work so hard to make this possible! Safety and efficacy of evobrutinib in relapsing multiple sclerosis. The Lancet Neurology: two multicentre, randomised, double-blind, active-controlled, phase 3 trials - The Lancet Neurology thelancet.com/journals/laneu…

Clinical trials in relapsing MS are becoming harder and harder…. Evobrutinib in multiple sclerosis: challenges and unmet goals - The Lancet Neurology thelancet.com/journals/laneu…

#AFRICTRIMS is long overdue. Fantastic news!

⁦Fantastic presentation from ⁦Dr Benjamin P Trewin⁩ regarding his data on optimal therapeutic dosing of corticosteroids at #MOGAD onset delaying time to first relapse ECTRIMS. Great audience discussions ⁦Sydney Health⁩ ⁦Kids Research⁩ ⁦⁦⁦

Great news! Hercules trial results in non-relapsing secondary-progressive #MS #SPMS. #Tolebrutinib reduced 6-month disability progression by 31% compared to placebo (P=0.0026). Liver monitoring will be very important. #ECTRIMS2024

Was so cool to be part of the ECTRIMS late breaking session today and share our results on depression genetic burden and it's association with #MultipleSclerosis disease activity & progression.

Live at #ECTRIMS2024: Prof. Kerstin Hellwig (Kerstin Hellwig) from Ruhr-Universität Bochum, has been awarded the 2024 Rachel Horne Prize for Women’s Research in MS. Join us in congratulating Prof. Hellwig for her invaluable contributions to women's health!

Congratulations to ⁦Kerstin Hellwig⁩ , the awardee of the #RachelHornePrizeforMS2024, receiving her award from ⁦Rachel Horne⁩ and ⁦Mar Tintore⁩ #ECTRIMS2024. ⁦ECTRIMS⁩

Yes - very low amount in breastmilk - without biological effect in Baby- 🫶👏🥂that’s the pored that BF under mabs is possible- also other indications as NMOSD for example.

Quick correction for those who attended the awesome ECTRIMS MS and Diet session by AnnekeVdWalt. This is the corrected slide acknowledgement, but I will add that it relates specifically to the amazing PhD work of Karen Zoszak in the EatrightMS Dietetic Research in Multiple Sclerosis team.

Huge shout out to Olivia Wills in helping to move forward our understanding of brain health for MS #proudsupervisor #changemaker

Older people with #MultipleSclerosis see neurologists as adequate providers of comprehensive support, but should improve the attention to complementary medicine and empathy. Study using social support theory form University of Zurich ▶️ journals.sagepub.com/doi/full/10.11…